## Cellares' Cell Shuttle Platform Deployed in First Patient Infusions for Cabaletta Bio's CAR-T Therapy
Cellares Corporation has achieved a critical clinical milestone, with its automated Cell Shuttle platform being used to manufacture the CAR-T cell therapy for the first patient infusions in Cabaletta Bio's clinical trial. This marks a significant validation point for Cellares' integrated, automated manufacturing technology, moving it from a development-stage platform into active clinical use. The deployment signals a potential shift in the scalability and consistency of advanced cell therapies, which have historically faced complex and variable manual production challenges.

The therapy in question is Cabaletta Bio's CABA-201, a CD19-targeted CAR T-cell therapy being investigated for autoimmune diseases. The use of the Cell Shuttle for these initial patient doses demonstrates a direct application of Cellares' technology in a live clinical setting. For Cabaletta, leveraging an automated, closed-system platform like the Cell Shuttle could help streamline its clinical supply chain and reduce manufacturing variability as it advances its therapeutic candidates.

The successful integration of this platform into a real-world trial creates pressure on the broader cell therapy manufacturing sector. It raises the benchmark for production technology, potentially accelerating the industry's move toward automation to improve reliability, reduce costs, and increase patient access. This development will be closely watched by other biotechs and large pharma partners evaluating next-generation manufacturing solutions for their own cell therapy pipelines.
---
- **Source**: Seeking Alpha
- **Sector**: The Lab
- **Tags**: CAR-T Therapy, Cell Therapy Manufacturing, Clinical Trials, Biotechnology, Automation
- **Credibility**: unverified
- **Published**: 2026-04-15 06:52:48
- **ID**: 65026
- **URL**: https://whisperx.ai/en/intel/65026